404 related articles for article (PubMed ID: 27614723)
21. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study.
Swedberg K; Komajda M; Böhm M; Borer JS; Ford I; Dubost-Brama A; Lerebours G; Tavazzi L;
Lancet; 2010 Sep; 376(9744):875-85. PubMed ID: 20801500
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of ivabradine in patients with chronic systolic heart failure according to blood pressure level in SHIFT.
Komajda M; Böhm M; Borer JS; Ford I; Robertson M; Manolis AJ; Tavazzi L; Swedberg K;
Eur J Heart Fail; 2014 Jul; 16(7):810-6. PubMed ID: 24961493
[TBL] [Abstract][Full Text] [Related]
23. Twenty-four-hour heart rate lowering with ivabradine in chronic heart failure: insights from the SHIFT Holter substudy.
Böhm M; Borer JS; Camm J; Ford I; Lloyd SM; Komajda M; Tavazzi L; Talajic M; Lainscak M; Reil JC; Ukena C; Swedberg K
Eur J Heart Fail; 2015 May; 17(5):518-26. PubMed ID: 25801408
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of the SIGNIFY trial.
Grassi G
Expert Opin Pharmacother; 2015; 16(12):1861-4. PubMed ID: 26153241
[TBL] [Abstract][Full Text] [Related]
25. Safety profile and efficacy of ivabradine in heart failure due to Chagas heart disease: a post hoc analysis of the SHIFT trial.
Bocchi EA; Rassi S; Guimarães GV;
ESC Heart Fail; 2018 Jun; 5(3):249-256. PubMed ID: 29266804
[TBL] [Abstract][Full Text] [Related]
26. Effect of ivabradine on numbers needed to treat for the prevention of recurrent hospitalizations in heart failure patients.
Rogers JK; Kielhorn A; Borer JS; Ford I; Pocock SJ
Curr Med Res Opin; 2015; 31(10):1903-9. PubMed ID: 26361063
[TBL] [Abstract][Full Text] [Related]
27. Non-adherence to ivabradine and placebo and outcomes in chronic heart failure: an analysis from SHIFT.
Böhm M; Lloyd SM; Ford I; Borer JS; Ewen S; Laufs U; Mahfoud F; Lopez-Sendon J; Ponikowski P; Tavazzi L; Swedberg K; Komajda M
Eur J Heart Fail; 2016 Jun; 18(6):672-83. PubMed ID: 26952245
[TBL] [Abstract][Full Text] [Related]
28. Ivabradine in Severe Aortic Stenosis with Poor Left Ventricular Ejection Fraction.
Huang D; Chan PH; Lam CC; Shea PC; Yiu KH; Tse HF; Siu CW
J Heart Valve Dis; 2015 Jul; 24(4):433-5. PubMed ID: 26897811
[TBL] [Abstract][Full Text] [Related]
29. Impact of a pure reduction in heart rate for the treatment of left ventricular dysfunction: clinical benefits of ivabradine in the BEAUTIFUL trial.
Danchin N
Therapie; 2009; 64(2):111-4. PubMed ID: 19664404
[TBL] [Abstract][Full Text] [Related]
30. Ivabradine, a novel medication for treatment of heart failure with reduced ejection fraction.
Foster JL; Bobadilla RV
J Am Assoc Nurse Pract; 2016 Nov; 28(11):576-582. PubMed ID: 27215699
[TBL] [Abstract][Full Text] [Related]
31. Ivabradine in heart failure--no paradigm SHIFT…yet.
Teerlink JR
Lancet; 2010 Sep; 376(9744):847-9. PubMed ID: 20801501
[No Abstract] [Full Text] [Related]
32. Ivabradine: Do the Benefits Outweigh the Risks?
Alshammari TM
J Cardiovasc Pharmacol Ther; 2017 May; 22(3):210-218. PubMed ID: 27698078
[TBL] [Abstract][Full Text] [Related]
33. Effect of Ivabradine on Endothelial Function in Patients with Stable Angina Pectoris: Assessment with the Endo-PAT 2000 Device.
Jedlickova L; Merkovska L; Jackova L; Janicko M; Fedacko J; Novakova B; Chmelarova A; Majernik J; Pella D
Adv Ther; 2015 Oct; 32(10):962-70. PubMed ID: 26525390
[TBL] [Abstract][Full Text] [Related]
34. Rate control with ivabradine: angina pectoris and beyond.
Parakh N; Bhargava B
Am J Cardiovasc Drugs; 2011; 11(1):1-12. PubMed ID: 21090826
[TBL] [Abstract][Full Text] [Related]
35. Ivabradine: beyond heart rate control.
Riccioni G; Vitulano N; D'Orazio N
Adv Ther; 2009 Jan; 26(1):12-24. PubMed ID: 19165437
[TBL] [Abstract][Full Text] [Related]
36. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial.
Böhm M; Swedberg K; Komajda M; Borer JS; Ford I; Dubost-Brama A; Lerebours G; Tavazzi L;
Lancet; 2010 Sep; 376(9744):886-94. PubMed ID: 20801495
[TBL] [Abstract][Full Text] [Related]
37. Clinical profiles and outcomes in patients with chronic heart failure and chronic obstructive pulmonary disease: an efficacy and safety analysis of SHIFT study.
Tavazzi L; Swedberg K; Komajda M; Böhm M; Borer JS; Lainscak M; Robertson M; Ford I;
Int J Cardiol; 2013 Dec; 170(2):182-8. PubMed ID: 24225201
[TBL] [Abstract][Full Text] [Related]
38. Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: a post-hoc analysis of SHIFT.
Komajda M; Tavazzi L; Swedberg K; Böhm M; Borer JS; Moyne A; Ford I;
Eur J Heart Fail; 2016 Sep; 18(9):1182-9. PubMed ID: 27210035
[TBL] [Abstract][Full Text] [Related]
39. Impact of Ivabradine on Health-Related Quality of Life of Patients with Ischaemic Chronic Heart Failure.
Sallam M; Al-Saadi T; Alshekaili L; Al-Zakwani I
Curr Vasc Pharmacol; 2016; 14(5):481-486. PubMed ID: 27145825
[TBL] [Abstract][Full Text] [Related]
40. Ivabradine in combination with beta-blocker reduces symptoms and improves quality of life in elderly patients with stable angina pectoris: age-related results from the ADDITIONS study.
Müller-Werdan U; Stöckl G; Ebelt H; Nuding S; Höpfner F; Werdan K;
Exp Gerontol; 2014 Nov; 59():34-41. PubMed ID: 25193811
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
